Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15493MR)

This product GTTS-WQ15493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11774MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ7475MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ14913MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ9871MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ4232MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ6423MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ10417MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ12968MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW